262 546

Cited 37 times in

The predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast Cancer.

DC Field Value Language
dc.contributor.author구자승-
dc.contributor.author정우희-
dc.contributor.author정준-
dc.date.accessioned2015-04-24T16:53:08Z-
dc.date.available2015-04-24T16:53:08Z-
dc.date.issued2009-
dc.identifier.issn0368-2811-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/104357-
dc.description.abstractOBJECTIVE: The purpose of this study was to evaluate the impact of various pathologic and biologic factors in triple-negative breast cancer (TNBC) on chemotherapy response using in vitro ATP-based chemotherapy response assay (ATP-CRA). METHODS: Forty-seven cases of TNBC were included. Immunohistochemical stains for androgen receptor (AR), p53, CD10, c-kit, CK5/6, vimentin, bcl-2, E-cadherin, Ki-67 and epidermal growth factor receptor were performed. In vitro ATP-CRA was used to analyze chemosensitivity for 5-fluorouracil (5-FU), docetaxel, doxorubicin, epirubicin, vinorelbine, gemcitabine, methotrexate (MTX), oxaliplatin and paclitaxel. RESULTS: The results showed that all cytotoxic agents demonstrated the trend that E-cadherin-expressing cases had a higher cell death rate than E-cadherin-negative cases. Particularly, vinorelbine showed statistical significance (P = 0.004). Cases with AR expression showed higher cell death rates than those without in 5-FU and MTX (P = 0.012 and 0.014, respectively). CONCLUSIONS: E-cadherin and AR could be candidate predictive factors for chemotherapy response in TNBC. Further in vivo study is required to clarify their roles.-
dc.description.statementOfResponsibilityopen-
dc.format.extent560~568-
dc.relation.isPartOfJAPANESE JOURNAL OF CLINICAL ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenocarcinoma/drug therapy-
dc.subject.MESHAdenocarcinoma/metabolism-
dc.subject.MESHAdenocarcinoma/mortality-
dc.subject.MESHAdenosine Triphosphate/metabolism-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Agents/therapeutic use*-
dc.subject.MESHBiomarkers, Tumor/metabolism*-
dc.subject.MESHBreast Neoplasms/drug therapy*-
dc.subject.MESHBreast Neoplasms/metabolism*-
dc.subject.MESHBreast Neoplasms/mortality-
dc.subject.MESHCadherins/metabolism*-
dc.subject.MESHCarcinoma, Ductal, Breast/drug therapy-
dc.subject.MESHCarcinoma, Ductal, Breast/metabolism-
dc.subject.MESHCarcinoma, Ductal, Breast/mortality-
dc.subject.MESHCarcinoma, Medullary/drug therapy-
dc.subject.MESHCarcinoma, Medullary/metabolism-
dc.subject.MESHCarcinoma, Medullary/mortality-
dc.subject.MESHCell Death/drug effects-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHKi-67 Antigen/metabolism-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPredictive Value of Tests-
dc.subject.MESHProto-Oncogene Proteins c-bcl-2/metabolism-
dc.subject.MESHReceptors, Androgen/metabolism*-
dc.subject.MESHTumor Suppressor Protein p53/metabolism-
dc.titleThe predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast Cancer.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학)-
dc.contributor.googleauthorJa Seung Koo-
dc.contributor.googleauthorWoohee Jung-
dc.contributor.googleauthorJoon Jeong-
dc.identifier.doi10.1093/jjco/hyp065-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00198-
dc.contributor.localIdA03671-
dc.contributor.localIdA03727-
dc.relation.journalcodeJ01207-
dc.identifier.eissn1465-3621-
dc.identifier.pmid19531543-
dc.subject.keywordandrogen receptor-
dc.subject.keywordbreast cancer-
dc.subject.keywordchemosensitivity-
dc.subject.keywordE-cadherin-
dc.subject.keywordtriple negative-
dc.contributor.alternativeNameKoo, Ja Seung-
dc.contributor.alternativeNameJung, Woo Hee-
dc.contributor.alternativeNameJeong, Joon-
dc.contributor.affiliatedAuthorKoo, Ja Seung-
dc.contributor.affiliatedAuthorJung, Woo Hee-
dc.contributor.affiliatedAuthorJeong, Joon-
dc.contributor.affiliatedAuthor구자승-
dc.citation.volume39-
dc.citation.number9-
dc.citation.startPage560-
dc.citation.endPage568-
dc.identifier.bibliographicCitationJAPANESE JOURNAL OF CLINICAL ONCOLOGY, Vol.39(9) : 560-568, 2009-
dc.identifier.rimsid52616-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.